 |
Wenxin Zheng, M.D., tenure Professor of Pathology and Obstetrics and Gynecology, American board certified pathologist, director of the Gynecologic Pathology and Molecular Pathology program at the University of Arizona, graduated from Shanghai Medical College Fudan University and trained at Columbia University, Cornell University, and Brown University Medical Centers in anatomic pathology and gynecologic pathology. Dr. Zheng is an internationally recognized gynecologic pathologist with expertise in hormonal etiology of sporadic ovarian cancer, type II endometrial carcinogenesis, and hormone replacement therapy.
1982-1986 Intern and resident, Hospital of Obstetrics and Gynecology, Shanghai Medical College Fudan University China
1986-1989 Post Doctoral Scientist, College of Physicians and Surgeons1989-1991 Associate Research Scientist, Columbia University, New York, NY
1991-1995 Intern, Resident and Chief Resident, Pathology, The New York Hospital, Cornell University Medical College, New York, NY,
1995-1996 Gynecologic & Breast Pathology Fellow and Instructor, Department of Women and Infants’ HospitalPathology, Brown University, Providence, RI,
1996-2000 Assistant Professor of Pathology and Gynecology, Attending Pathologist, Department of Pathology University Southern California School of Medicine, Women & Children’s Hospital, Los Angeles, CA
2000-2005 Associate Professor, Director of Gynecologic Pathology and Fellowship for Gynecologic Pathology, Department of Pathology, Yale University School of Medicine,Yale - New Haven Hospital, New Haven, CT
2005-present Tenure Professor of Pathology and Gynecology, Director of Gynecologic and Molecular Pathology, Department of Pathology and Gynecology, The University of Arizona Medical College, University Medical Center and University Physicians Healthcare, Tucson, AZ
2005-2008 Chairman, Professor of Pathology, Gynecology and Oncology, Department of Pathology, Pathology Center, Shanghai Medical College Fudan University, Shanghai, China
2008-present Guest Professor of College of Medicine, Shandong University, Shandong, China
(*Corresponding author articles)
2). Bellve AR, Zheng W. Different pleiotypic actions of SGF, aFGF and bFGF. Ann N Y Acad Sci 1989; 564, 116-131.
3). Zheng W, Butwell T, Hecket L, Griswold M, Bellve AR. Pleiotypic actions of the seminiferous growth factor on two testis cell lines: comparisons with acidic and basic fibroblast growth factors. Growth Factor 1990; 3, 73-82
6). Zheng W, Wolf S, Kramer EE, Hoda S. Borderline serous tumor of the fallopian tube. Am J Surg Pathol 1996; 20, 30-35 [Pubmed] [Fulltext]
7). Zheng W, Magid MS, Kramer EE, Chen YT. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 1996; 148, 47-53 [Pubmed] [PDF]
8). *Zheng W, Cao P, Zheng M, Kramer EE, Godwin T. p53 and bcl-2 expression in endometrial adenocarcinoma. Comparison of serous and endometrioid subtypes (see comments). Gynecol Oncol 1996; 61, 167-174 [Pubmed] [PDF]
9). *Zheng W, Feng YJ, Gandhi M, Siu S, Hom E, Caputo T, Lauchlan SC. Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivity. Int J Gynecol Cancer 1996; 6, 235-240
10). *Zheng W, Sung CJ, Cao P, Cai R, Godwin TA, Kramer EE, Lauchlan SC. The early occurrence and prognostic significance of p53 in primary carcinoma of the fallopian tube. Gynecol Oncol 1997; 64, 38-48 [Pubmed] [PDF]
11). *Zheng W, Sung CJ, Hanna I, Lambert-Messerlian G, Steinhoff M, Lauchlan SC. Inhibin alpha and beta subunits of inhibin/activin as markers for gonadal sex cord-stromal differentiation. Int J Gynecol Pathol, 1997; 16, 263-271 [Pubmed] [PDF]
15) *Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Schneyer A, Lauchlan SC, Felix JC. Imbalanced expression of inhibin and activin subunits of in primary epithelial ovarian cancer. Gynecol Oncol 1998; 69, 23-31 [Pubmed] [PDF]
16) *Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 as an significant diagnostic marker for uterine surface carcinoma--precursor lesion of uterine papillary serous carcinoma. Am J Surg Pathol 1998, 22: 1463-1473. [Pubmed] [Fulltext]
17) *Zheng W, Lauchlan SC. Inhibin and Activin: Their roles in ovarian tumorigenesis and their diagnostic utility in surgical pathology practice. Appl Immunohistochem Mol Morphol 1999, 7, 29-38.
18) Amezcua CA, *Zheng W, Muderspach L, Felix JC. Down regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. Gynecol Oncol 1999, 73, 126-136. [PDF]
20) *Zheng W, Lu J, Luo F, Zheng Y, Feng Y-J, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by FSH and inhibition of the effect by LH. Gynecol Oncol 2000, 76: 80-88. [Pubmed] [PDF]
21).*Zheng W, Luo F, Lu J, Baltayan A, Press M, Zhang ZF, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer (see comment). Gynecol Oncol, 2000, 76: 294-300. [Pubmed] [PDF]
22). Sung J, Quddus M, Zheng Y, Zhang ZF, Lauchlan SC, *Zheng W. p53 serves as a significant prognostic marker in endometrial carcinomas. Int J Gynecol Cancer, 2000, 10: 119-127.
23).*Zheng W, Lu JJ, Luo F, Zhang L, Cho M, Wang CY, Stanczyk F. Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. Am J Reprod Immunol, 2000, 44, 104-113. [Pubmed] [PDF]
24). Lu JJ, Zheng Y, Kang X, Yuan J-M,. Lauchlan SC, *Zheng W. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol, 2000, 79: 158-168. [Pubmed] [PDF]
25) Amezcua CA, Lu JJ, Stanczyk FZ, *Zheng W. Apoptosis may be an early event of Progestin Therapy for endometrial hyperplasia. Gynecol Oncol 2000, 79, 169-176. [Pubmed] [PDF]
26) Wang J, Luo F, Chen P, Liu P, *Zheng W. VEGF Expression and enhanced production by gonadotropins in ovarian epithelial tumors. Intl J Cancer 2002, 97: 163-167 [Pubmed] [PDF]
29). Wang J, Ling-Chang L, Schwarts PE, Lauchlan SC, *Zheng W. Quantitative analysis of FSHR in ovarian epithleial tumors: a novel approach to explain the field effect of ovarian cancer development in peritoneal cavity. Intl J Cancer, 2003, 103: 328-334. [Pubmed] [PDF]
30). Wang S, Pudney J, Song J, Mor G, Schwartz PE, *Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia—precursor of endometrial cancer. Gynecol Oncol, 2003, 88: 108-117. [Pubmed] [PDF]
31). *Zheng W, Senturk BZ, Parkash V. Inhibin Immunohistochemical Staining: A practical approach for the surgical pathologist in the diagnosis of ovarian sex cord-stromal tumors. Adv Anat Pathol, 2003, 10: 27-38. [Pubmed] [PDF]
34). Schwartz PE, and *Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol Oncol, 2003, 90: 644-650. [Pubmed] [PDF]
37) Zheng W, Baker HE, Mutter GL. Involution of PTEN-Null Endometrial Glands with Progestin Therapy. Gynecol Oncol, 2004, 92: 1008-1013. [Pubmed] [PDF]
38). *Zheng W, Liang SX, Yu H, Rutherford, T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: a morphological study. Intl J Surg Pathol, 2004, 12: 207-223. [Pubmed] [PDF]
39). Liang SX, Cheng L, Chambers SK, Zhou Y, Schwartz PE, *Zheng W. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: a molecular study. Intl J Surg Pathol, 2004, 12: 319-331 [Pubmed] [PDF]
41). Fadare O, *Zheng W. HER2 protein (p185HER2) is only rarely overexpressed in cervical cancer. Intl J Gynecol Pathol, 2004, 23: 410-411.
43). Ma L, Fisk J, Crum CP, Zhang R, Ulukus EC, *Zheng W. Cervcial eosinophilic dysplasia, a newly identified variant of high-grade squamous intraepithelial neoplasia of the cervix. Am J Surg Pathol, 2004, 28: 1474-1484. [Pubmed] [PDF]
45). Fadare O, Zheng W*. Histologic dating of the endometrium: Accuracy, reproducibility, and practical value. Adv Anat Pathol, 2005, 12 39-46. [Pubmed] [PDF]
46). *Zheng W, Schwartz PE. Serous EIC as an early form of UPSC. Recent progress of its pathogenesis and current opinions of clinical management, Gynecol Oncol, 2005, 96: 579-582. [Pubmed] [PDF]
48). *Zheng W, Li N, Wang J, Ulukus EC, Murat Ulukus M, Arici A, and Liang SX. Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis. Intl J Gynecol Pathol, 2005, 24: 164-172. [Pubmed] [PDF]
51). Hileeto D, Fadare O, Martel M, *Zheng W. Endometrial polyp in postmenopausal women associated with an increased risk of cancer involvement. World Oncology Surgical Journal, 2005, 3: 8-10.
54). Oluwole Fadare O, Reddy H, Wang J, Hileeto D, Schwartz PE and *Zheng W. E-cadherin and beta-catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World Journal of Surgical Oncology. 2005, 3: 38. [Pubmed] [PDF]
58). Fadare O, Liang SX, E. Cagnur Ulukus EC, Chambers SK, and *Zheng W. Precursors of Endometrial Clear Cell Carcinoma. Am J Surg Pathol, 2006, 30: 1519-1530. [Pubmed] [PDF]
61) Risch HA, Bale AE, Beck PA and Zheng W. PGR +331A/G and Increased Risk of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prevention, 2006 15: 1738-1741 [Pubmed] [PDF]
65) *Zheng W, Liang SX, Yi XF, Ulukus EC, Davis J, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol, 2007, 26: 38-52. [Pubmed] [PDF]
70) Fadare O, Yi X, Liang SX, Ma Y, *Zheng W. Variations of Mitotic Index in Normal and Dysplastic Squamous Epithelium of the Uterine Cervix as a Function of Endometrial Maturation. Modern Pathol, 2007, 20: 1000-8. [Pubmed] [PDF]
72) *Zheng W, H Wang. Precursor lesions and its carcinogenesis of type II endometrial cancer. J Clin Exp Pathol, 2007, 23: 129-132 (as a format of Expert Forum).
73) *Zheng W, Wang H. The Borderline tumor: consensus and dilemma. J Clin Exp Pathol, 2007, 23: 257-261 (as a format of Expert Forum).
74) Wang H and *Zheng W. Precancers of type II endometrial cancer: diagnosis and clinical management. Chinese Pathol J, 2007, 36: 505-507 (as an invited commentary).
75) Yi X, *Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Current Opinion Obstet Gynecol, 2008, 20: 20-25. [Pubmed] [PDF]
76) *Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The Oncofetal Protein IMP3: A Novel Biomarker for Endometrial Serous Carcinoma. Am J Surg Pathol, 2008, 32: 304-315. [Pubmed] [PDF]
78) Fadare O and *Zheng W. Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagnostic Pathology 2008, 3:6 (invited commentary). [Pubmed] [PDF]
79) Jia L, Liu YJ, Yi X, Liang SX, Miron A, Crum CP, *Kong B, *Zheng W. Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting its Precancer Nature for Endometrial Serous Carcinoma. Clinical Cancer Res, 2008;14: 2263-9. [Pubmed] [PDF]
81)Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X,* Zheng W , Wondrak GT, Wong PK, Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008, 29:1235-43 PMID: 18413364 [PDF]
85)Zhang Z, Jia L, Feng Y, Zheng W*. Overexpression of follicle-stimulating hormone receptor facilitates thedevelopment of ovarian epithelial cancer. Cancer Lett.2009 Jan 30. [Epub ahead of print]. PMID: 19181441 [PDF]
86) Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, *Zheng W. Molecular Identification of “Latent Precancers” for Endometrial Serous Carcinoma in Benign Appearing Endometrium. Am J Pathol, accepted in Feb. 2009 and published in May 12, 2009 [PDF]
87) Yi X, Zhou Y, *Zheng W, Chambers SK. HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer. Aust N Z J Obstet Gynaecol. 2009;49:93-8. [PDF]
Monday, May 18, 2009 All contents ©2008 Arizona Board of Regents.
All Rights Reserved.